Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo



Request an Appointment



Contact us with Questions

Expand Content

Mellen Center for Multiple Sclerosis

Mellen Center for Multiple Sclerosis offers state-of-the-art resources to provide the most advanced specialized care, supported by an extensive program of research and education. The Mellen Center is one of the largest and most comprehensive programs for MS care and research worldwide, managing more than 20,000 patient visits every year. Basic and clinical research conducted at Cleveland Clinic sheds new light on MS every year.

About the Center
Mellen Center's mission, brief overview and news archive.
Diseases & Conditions
View a list of diseases and conditions treated at Mellen Center. Including, multiple sclerosis and pediatric multiple sclerosis.
Diagnostics & Testing
From lumbar punctures to imaging services, learn about the diagnosis and testing options available to Mellen Center patients.
Treatment & Services
Treatment options including, alternative therapies, FDA approved medications and rehabilitation services.
Our Doctors
View a list of Mellen Center physicians, collaborating scientists and advance practicing clinicians.
Mellen Center locations, driving directions, contact information and MyChart access links.
Research & Clinical Trials
View a current enrolling list of clinical trials and research information.
Patient Education
Symptom management care tips, information on needle disposal, glossary of terms and informational webcasts.
For Medical Professionals
Educational opportunities, fellowships and electives.

Patient Resources



On Friday 14 November, the FDA approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis. Lemtrada is administered by annual IV infusion. It has potent efficacy and generally is well tolerated. However, it has several potential safety issues, including infection and particularly risk of other autoimmune disorders - thyroid disease, immune thrombocytopenia (decrease in platelets, the cells that stop bleeding), and kidney disease. Because of its safety profile, it is anticipated that use of Lemtrada generally will be reserved for patients who have had an inadequate response to two or more other MS medications.

Clinical focus in MS: Novel approaches to Progressive Disease

Novel MS Drugs Advance

Dr. Mary Willis - Multiple Sclerosis

Early Cleveland Clinic trial of stem cells for multiple sclerosis shows promise